BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28194061)

  • 1. Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib.
    Ganguly S; Lakshmaiah KC; Jacob LA; Babu S; Dasappa L; Govind Babu KS
    Indian J Hematol Blood Transfus; 2017 Mar; 33(1):82-86. PubMed ID: 28194061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
    Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
    Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy.
    Xia L; Qian W; Yang M; Li Q; Liu F; Xie Y
    Onco Targets Ther; 2015; 8():2485-92. PubMed ID: 26392775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Three Prognostic Scoring Systems in Predicting the Response and Outcome in Pediatric Chronic Myeloid Leukemia Chronic Phase on Frontline Imatinib.
    Ganta RR; Nasaka S; Linga VG; Gundeti S; Maddali LS; Digumarti RR
    Indian J Med Paediatr Oncol; 2017; 38(3):282-286. PubMed ID: 29200674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Values of Different Prognostical Score Systems in Evaluation of Clinical Efficacy for Patients with Newly Diagnosed Chronic Myeloid Leukemia].
    Wang PP; Zhang PP; Zhang J; Xi YM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):723-728. PubMed ID: 31204922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib.
    Chhikara S; Sazawal S; Singh K; Chaubey R; Pati H; Tyagi S; Mahapatra M; Saxena R
    South Asian J Cancer; 2018; 7(4):258-262. PubMed ID: 30430096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib.
    Tao Z; Liu B; Zhao Y; Wang Y; Zhang R; Han M; Zhang L; Li C; Ru K; Mi Y; Wang J
    Leuk Res; 2014 Sep; 38(9):1030-5. PubMed ID: 24996976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?
    Kanakasetty GB; Thanky AH; Kuntegowdanahalli L; Dasappa L; Jacob L; Mallekavu SB; Lakkavalli R; Kadabur L; Antapura R
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):375-381. PubMed ID: 28502460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
    Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
    Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study.
    Yang X; Bai Y; Shi M; Zhang W; Niu J; Wu C; Zhang L; Xu Z; Liu X; Chen Y; Sun K
    Cancer Manag Res; 2020; 12():1293-1301. PubMed ID: 32110103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.
    Huang J; Wang L; Chen L; Qun H; Yajing X; Fangping C; Xielan Z
    Turk J Haematol; 2017 Mar; 34(1):10-15. PubMed ID: 27751981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients.
    Yamamoto E; Fujisawa S; Hagihara M; Tanaka M; Fujimaki K; Kishimoto K; Hashimoto C; Itabashi M; Ishibashi D; Nakajima Y; Tachibana T; Kawasaki R; Kuwabara H; Koharazawa H; Yamazaki E; Tomita N; Sakai R; Fujita H; Kanamori H; Ishigatsubo Y
    Cancer Sci; 2014 Jan; 105(1):105-9. PubMed ID: 24450386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical significance of Sokal, Hasford and EUTOS prognostic scoring systems in chronic myeloid leukemia].
    Feng G; Wang J; Jiang Y; Li Y; Ding M; Wang N; Wang X
    Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):743-6. PubMed ID: 25152126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population.
    Yahng SA; Jang EJ; Choi SY; Lee SE; Kim SH; Kim DW
    Int J Hematol; 2014 Aug; 100(2):132-40. PubMed ID: 24879034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
    Zhang XS; Gale RP; Huang XJ; Jiang Q
    Leukemia; 2022 Feb; 36(2):482-491. PubMed ID: 34413457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
    Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era-experience from a tertiary oncology centre in Southern India.
    Kuntegowdanahalli LC; Kanakasetty GB; Thanky AH; Dasappa L; Jacob LA; Mallekavu SB; Lakkavalli RK; Kadabur LN; Haleshappa RA
    Ecancermedicalscience; 2016; 10():679. PubMed ID: 27899952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of three prognostic scoring systems on evaluating the prognosis for patients with chronic myeloid leukemia].
    Huang J; Zhao X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 41(8):809-14. PubMed ID: 27600007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Stratification of Chronic Myeloid Leukemia According to Different Prognostic Scores.
    Aijaz J; Junaid N; Asif Naveed M; Maab R
    Cureus; 2020 Mar; 12(3):e7342. PubMed ID: 32313783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of optimal cytogenetic responses at 6 and 12 months in patients with chronic myeloid leukemia in chronic phase treated with imatinib.
    Milosevic V; Jovanovic MP; Bukumirić Z; Djordjevic V; Jovanovic J; Fekete MD; Lekovic D; Bogdanovic A
    J BUON; 2021; 26(3):1070-1079. PubMed ID: 34268974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.